Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor

Structural insight into substrate and inhibitor discrimination by human P-glycoprotein

(2019) Amer Alam et al.   SCIENCE

Tetrazoles via Multicomponent Reactions

(2019) Constantinos G. Neochoritis et al.   CHEMICAL REVIEWS

Affinity-Based Protein Profiling Reveals Cellular Targets of Photoreactive Anticancer Inhibitors

(2019) Nan Ma et al.   ACS Chemical Biology

477PAn international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours

(2019) C G C A Jackson et al.   ANNALS OF ONCOLOGY

Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration

(2018) Peter Matzneller et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1

(2018) Amer Alam et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation

(2018) Youngjin Kim et al.   SCIENCE

A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies.

(2018) Wen Wee Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

ATP-binding Cassette Exporters: Structure and Mechanism with a Focus on P-glycoprotein and MRP1

(2017) Maite Rocío Arana et al.   CURRENT MEDICINAL CHEMISTRY

Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature

(2016) Meaghan Krohe et al.   Patient Preference and Adherence

Multiple Drug Transport Pathways through Human P-Glycoprotein

(2015) James W. McCormick et al.   BIOCHEMISTRY

Mapping the Binding Site of the Inhibitor Tariquidar That Stabilizes the First Transmembrane Domain of P-glycoprotein

(2015) Tip W. Loo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer

(2015) K.-W. Lee et al.   ONCOLOGIST

In Vivo Imaging of Multidrug Resistance Using a Third Generation MDR1 Inhibitor

(2014) Melissa M. Sprachman et al.   BIOCONJUGATE CHEMISTRY

Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers

(2014) Tae-Eun Kim et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Increased Permeability-Glycoprotein Inhibition at the Human Blood-Brain Barrier Can Be Safely Achieved by Performing PET During Peak Plasma Concentrations of Tariquidar

(2014) W. C. Kreisl et al.   JOURNAL OF NUCLEAR MEDICINE

A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer

(2014) Hyun Jung Lee et al.   Cancer Research and Treatment

Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function

(2014) Frances Jane Sharom   Frontiers in Oncology

Sustained Increase in the Oral Bioavailability of Loperamide after a Single Oral Dose of HM30181, a P-glycoprotein Inhibitor, in Healthy Male Participants

(2013) Yu-Jung Cha et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Molecular Docking Characterizes Substrate-Binding Sites and Efflux Modulation Mechanisms within P-Glycoprotein.

(2013) Ricardo J. Ferreira et al.   Journal of Chemical Information and Modeling

Development and Evaluation of a Novel Microemulsion Formulation of Elacridar to Improve its Bioavailability

(2013) Ramola Sane et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Refined structures of mouse P-glycoprotein

(2013) Jingzhi Li et al.   PROTEIN SCIENCE

Tolerability and Pharmacokinetics of a New P-Glycoprotein Inhibitor, HM30181, in Healthy Korean Male Volunteers: Single- and Multiple-Dose Randomized, Placebo-Controlled Studies

(2012) Tae-Eun Kim et al.   CLINICAL THERAPEUTICS

Structure–Activity Relationships of Tariquidar Analogs as Multidrug Resistance Modulators

(2009) Ilza K. Pajeva et al.   AAPS Journal

ABC Efflux Pump-Based Resistance to Chemotherapy Drugs

(2009) Paul D. W. Eckford et al.   CHEMICAL REVIEWS

Intravenous-to-Oral Switch in Anticancer Chemotherapy: A Focus on Docetaxel and Paclitaxel

(2009) S L W Koolen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel

(2009) Jin-Oh Kwak et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding

(2009) S. G. Aller et al.   SCIENCE

Paclitaxel and docetaxel in the treatment of breast cancer

(2008) Emmanouel Saloustros et al.   EXPERT OPINION ON PHARMACOTHERAPY

Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

(2008) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE